J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector. The FDA granted approval to AstraZeneca AZN and partner Daiichi’s novel TROP2 ...

JNJ beat Q4 estimates for both earnings and sales, with earnings of $2.04 per share and $22.5 billion in sales. The FDA granted approval to AstraZeneca/Daiichi's Dato-DXd for previously treated ...

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Laurent Blanc Formation: 4 - 2 - 3 - 1 Manager: Nourredine Zekri ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade ... could be peak sales of around $5 billion for the drug. Near-term readouts include ...

Issei Hyodo's first date with his new girlfriend ends poorly when she turns into a monster and stabs him in the stomach. Luckily, he's saved by Rias, the buxom president of his school's Occult ...

5 In my clinical practice I follow these studies’ design ... B7-H3 and its treatment potential as a subsequent therapy for SCLC. Ifinatamab deruxtecan [I-DXd; DS-7300 is an ADC that targets B7-H3, ...

Watch all the latest action in the X Games.